{
    "clinical_study": {
        "@rank": "129360", 
        "arm_group": {
            "arm_group_label": "Subutinib Maleate capsules", 
            "arm_group_type": "Experimental", 
            "description": "Dose escalation will be dependent on any dose limiting toxicities"
        }, 
        "brief_summary": {
            "textblock": "1. purpose:  to explore the maximum tolerated dose, dose-limiting toxicity of oral\n           Subutinib Maleate capsules and rational dosage regimen for phase \u2161 study\n\n        2. Experimental Design\uff1a  A phase \u2160 study of  single-center\n\n        3. Test drug: Subutinib Maleate capsules\n\n        4. Sample size\u226520"
        }, 
        "brief_title": "A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor", 
        "detailed_description": {
            "textblock": "The primary objective of this study is to explore the maximum tolerated dose, dose-limiting\n      toxicity of oral Subutinib Maleate capsules and rational dosage regimen for phase \u2161 study,\n      to investigate the pharmacokinetics of single and multiple oral doses of Subutinib Maleate\n      capsules."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have histologically or cytologically confirmed solid tumors\n\n          -  Subjects who have failed standard effective therapy or have a diagnosis for which no\n             standard effective treatment is available;\n\n          -  Aged 18 to 70 years old; Eastern Cooperative Oncology Group (ECOG) performance status\n             (PS) 0-2; Life expectancy greater than 3 months;\n\n          -  If the subject has been given other chemotherapy drugs, it's necessary   to\n             discontinue them more than 4 weeks. If the chemotherapy drugs are Nitrosoureas and\n             Mitomycin C, it's necessary to discontinue them more than 6 weeks. If the subject has\n             accepted major surgery, it's necessary to wait more than 4 weeks before the subject\n             participating in this study.\n\n          -  Blood test: Hb\u2265100g/L(no blood transfusion within 14 days);\n             ANC\u22651.5\u00d7109/L,  PLT\u2265100\u00d7109/L\n\n          -  Biochemistry: TBIL and ALT and AST and Cr are in normal range, or creatinine\n             clearance \u226560ml/min; Triglyceride\u22643.0mmol/L; Cholesterol \u22647.75mmol/L.\n\n          -  Doppler ultrasound measurement: LVEF \u2265 LLN\n\n          -  Female subjects should agree to take contraceptives during the study and within 6\n             months after the study (such as intrauterine device [IUD], contraceptive drugs or\n             condoms); within 7 days before they enter the study, their serum or human chorionic\n             gonadotropin should be negative, and must be in the non-lactation period; male\n             subjects should agree to take contraceptives during the study and within 6 months\n             after the study.\n\n          -  The subject is willing to participate in this study, and he/she has signed the\n             Informed Consent Form, with good compliance.\n\n        Exclusion Criteria:\n\n          -  The subject has participated in other drug clinical research in the past 4 weeks.\n\n          -  The subject is accompanied with several factors which will influence the\n             investigational drug administration orally, such as inability to swallow or after\n             gastrointestinal resection or chronic diarrhea or intestinal obstruction.\n\n          -  Central nervous system metastasis definitely.\n\n          -  The subject is suffering from hypertension or myocardial ischemia or myocardial\n             infarction or arrhythmia (including QT interval\u2265440ms) or Grade I heart failure.\n\n          -  If the subject's systolic BP is over 140mmhg, with diastolic BP over 90mmhg, or the\n             subject's blood pressure is well-controlled, he/she is not permitted to enroll in\n             this study as well.\n\n          -  The subject's urinalysis displays that urinary protein \u2265 ++ , combined with 24-hour\n             urinary protein > 1.0g.\n\n          -  The subject's is suffering from wounds or fractures which can not be cured for long\n             time.\n\n          -  Abnormal coagulation: The subject has bleeding tendency such as active peptic ulcer\n             or the subject is receiving thrombolytic or anticoagulant therapy.\n\n          -  There are pre-dosing arterial/venous thrombotic events on this subject, such as\n             cerebrovascular accident (including TIA) or deep vein thrombosis or pulmonary\n             embolism.\n\n          -  The subject is accepting anticoagulants or vitamin K antagonists such as warfarin or\n             heparin or analogue therapy; If the subject's INR \u2264 1.5, he/she is allowed to use\n             small doses of warfarin (1mg oral q d) or small doses of aspirin(less than 100mg each\n             day), and the purpose of the treatment should be prevention.\n\n          -  Abnormal thyroid function.\n\n          -  There is history of mental drug abuse occurred in the subject, or the subject is\n             suffering from mental disorders.\n\n          -  There is history of immunodeficiency occurred in the subject, including HIV positive\n             or other acquired or congenital immunodeficiency diseases, or the subject has\n             accepted organ transplant before.\n\n          -  Lung squamous cell carcinoma.\n\n          -  The subject has received small molecule targeted drug therapy of inhibition of\n             VEGFR-2 and PDGFR\u03b2\n\n          -  According to the investigator's judgment, there are concomitant diseases which will\n             seriously do harm to the subject's safety or obstruct the subject to complete the\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806376", 
            "org_study_id": "SBYN-\u2160-01"
        }, 
        "intervention": {
            "arm_group_label": "Subutinib Maleate capsules", 
            "description": "Dose escalation will be dependent on any dose limiting toxicities", 
            "intervention_name": "Subutinib Maleate capsules", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Maleic acid"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 7, 2013", 
        "location": {
            "contact": {
                "email": "cao_junning@hotmail.com", 
                "last_name": "Cao j nin, doctor", 
                "phone": "02164175590", 
                "phone_ext": "8216"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Shanghai Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics", 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Li jin, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Dose-limiting toxicity\uff0c maximum tolerated dose.", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806376"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Subutinib Maleate pharmacokinetic parameters , include AUC, Cmax, Tmax, and t1/2", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "description": "The response of Subutinib Maleate on tumor.", 
                "measure": "Pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}